Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (7597)	8/10/2001 11:22:40 AM
From: toccodolce	Respond to of 14101

Hi, Just picked up this headliner off of yahoo finance. A European firm just signed a marketing deal with J&J for distribution rights in the US, Japan and the rest of the world except Europe. I found this interesting because Pennsaid is so far along the product cycle that DMX will most likely receive a higher payment and royalty fee. Plus with the M&A of OXO Chemie DMX's future looks even brighter. Hopefully DMX can achieve anticipated milestones (ie. EU, HC and FDA approval) A question: If DMX does receive EU approval how does that affect approval in Japan? Just a few facts and link to the article: biz.yahoo.com - experimental drug - company expected to receive $15 million in upfront payments and 15% in royalties - estimated total payments by J&J to $100 million - J&J will fund 75% of the rest of the clinical developments Tom